Yunfeng Shen

1.9k total citations · 2 hit papers
46 papers, 1.3k citations indexed

About

Yunfeng Shen is a scholar working on Molecular Biology, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Yunfeng Shen has authored 46 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 16 papers in Surgery and 14 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Yunfeng Shen's work include Pancreatic function and diabetes (12 papers), Liver Disease Diagnosis and Treatment (10 papers) and Diabetes Management and Research (6 papers). Yunfeng Shen is often cited by papers focused on Pancreatic function and diabetes (12 papers), Liver Disease Diagnosis and Treatment (10 papers) and Diabetes Management and Research (6 papers). Yunfeng Shen collaborates with scholars based in China, United States and Hong Kong. Yunfeng Shen's co-authors include Xiaojuan Jiao, Shucai Xiao, Qin Zhang, Xiaoyang Lai, Jianping Weng, Hua Liang, Xuan Xia, Kuanxiao Tang, Jinhua Yan and Yanhua Zhang and has published in prestigious journals such as PLoS ONE, The FASEB Journal and FEBS Letters.

In The Last Decade

Yunfeng Shen

43 papers receiving 1.3k citations

Hit Papers

The triglyceride-glucose index is a predictor for cardiov... 2023 2026 2024 2025 2023 2023 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The triglyceride-glucose index is a predictor for cardiovascular and all-cause mortality in CVD patients with diabetes or pre-diabetes: evidence from NHANES 2001–2018
    2023 237 citations Shucai Xiao, Xiaojuan Jiao et al. profile →
  2. SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis
    2023 76 citations Yunfeng Shen, Minxuan Xu et al. profile →

Peers

Yunfeng Shen
Iolanda Lázaro Spain
Qun Li China
Yanxiang Gao China
Dingkun Gui China
Li Cai China
Anil Bhanudas Gaikwad India
Karen SL Lam Hong Kong
Kengo Azushima Japan
Gaetano Pannitteri Italy
Flori R. Sari Japan
Iolanda Lázaro Spain
Yunfeng Shen
Citations per year, relative to Yunfeng Shen Yunfeng Shen (= 1×) peers Iolanda Lázaro

Countries citing papers authored by Yunfeng Shen

Since Specialization
Citations

This map shows the geographic impact of Yunfeng Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yunfeng Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yunfeng Shen more than expected).

Fields of papers citing papers by Yunfeng Shen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yunfeng Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yunfeng Shen. The network helps show where Yunfeng Shen may publish in the future.

Co-authorship network of co-authors of Yunfeng Shen

This figure shows the co-authorship network connecting the top 25 collaborators of Yunfeng Shen. A scholar is included among the top collaborators of Yunfeng Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yunfeng Shen. Yunfeng Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Ye, Zhenfeng, Jing Zhang, Zhou Xu, et al.. (2024). Pioglitazone ameliorates ischemia/reperfusion-induced acute kidney injury via oxidative stress attenuation and NLRP3 inflammasome. Human Cell. 37(4). 959–971. 7 indexed citations
4.
Mei, Jiaqi, Yi Li, Qi Cai, et al.. (2024). SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system. Translational Neurodegeneration. 13(1). 41–41. 35 indexed citations
5.
Liu, Xijuan, et al.. (2023). Plasma exosome miRNA-26b-3p derived from idiopathic short stature impairs longitudinal bone growth via the AKAP2/ERK1/2 axis. Journal of Nanobiotechnology. 21(1). 94–94. 9 indexed citations
6.
Jiao, Xiaojuan, Qin Zhang, Ping Peng, & Yunfeng Shen. (2023). HbA1c is a predictive factor of severe coronary stenosis and major adverse cardiovascular events in patients with both type 2 diabetes and coronary heart disease. Diabetology & Metabolic Syndrome. 15(1). 50–50. 8 indexed citations
7.
Jiao, Xiaojuan, Ping Peng, Qin Zhang, & Yunfeng Shen. (2023). Glucagon-Like Peptide-1 Receptor Agonist and Risk of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials. Clinical Drug Investigation. 43(12). 915–926. 5 indexed citations
8.
Zhang, Jing, Hongguang Sheng, Xiaoyi Tang, et al.. (2022). Non-steroidal anti-inflammatory drugs and clinical outcomes in patients with COVID-19. Frontiers in Cellular and Infection Microbiology. 12. 935280–935280. 2 indexed citations
9.
Chen, Xinyue, Zhangwang Li, Jiashu Han, et al.. (2022). Advances in the study of RNA-binding proteins in diabetic complications. Molecular Metabolism. 62. 101515–101515. 16 indexed citations
10.
Zhang, Jing, Fuwei Liu, Zhangwang Li, et al.. (2022). Liver Fibrosis Scores and Clinical Outcomes in Patients With COVID-19. Frontiers in Medicine. 9. 829423–829423. 12 indexed citations
11.
12.
Xue, Guohui, Fangfang Li, Xiaoyang Lai, et al.. (2020). Combination of asprosin and adiponectin as a novel marker for diagnosing non-alcoholic fatty liver disease. Cytokine. 134. 155184–155184. 38 indexed citations
13.
Shen, Yunfeng, et al.. (2020). Altered DNA methylation of TRIM13 in diabetic nephropathy suppresses mesangial collagen synthesis by promoting ubiquitination of CHOP. EBioMedicine. 51. 102582–102582. 35 indexed citations
14.
Zou, Fang, Ling Wang, Han Liu, et al.. (2019). Sophocarpine Suppresses NF-κB-Mediated Inflammation Both In Vitro and In Vivo and Inhibits Diabetic Cardiomyopathy. Frontiers in Pharmacology. 10. 1219–1219. 24 indexed citations
15.
16.
He, Wei, Wengen Zhu, Qilin Cao, et al.. (2016). Generation of Mesenchymal-Like Stem Cells From Urine in Pediatric Patients. Transplantation Proceedings. 48(6). 2181–2185. 18 indexed citations
17.
Tang, Kuanxiao, Xiaoyan Xiao, Dayue Liu, et al.. (2014). Autografting of bone marrow mesenchymal stem cells alleviates streptozotocin-induced diabetes in miniature pigs: Real-time tracing with MRI in vivo. International Journal of Molecular Medicine. 33(6). 1469–1476. 15 indexed citations
18.
Lü, Lin, Min Feng, Jian Gu, et al.. (2013). Restoration of intrahepatic regulatory T cells through MMP-9/13-dependent activation of TGF-  is critical for immune homeostasis following acute liver injury. Journal of Molecular Cell Biology. 5(6). 369–379. 36 indexed citations
19.
Yu, Jianzhong, Jianping Hu, Xiaomeng Dai, et al.. (2013). SCN5A mutation in Chinese patients with arrhythmogenic right ventricular dysplasia. Herz. 39(2). 271–275. 20 indexed citations
20.
Liu, Qiang, Yunfeng Shen, Sanling Liu, Jianping Weng, & Jinsong Liu. (2011). Crystal structure of E339K mutated human glucokinase reveals changes in the ATP binding site. FEBS Letters. 585(8). 1175–1179. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Iolanda Lázaro Breakdown of academic impact, for papers by Qun Li Breakdown of academic impact, for papers by Yanxiang Gao Breakdown of academic impact, for papers by Dingkun Gui Breakdown of academic impact, for papers by Li Cai Breakdown of academic impact, for papers by Anil Bhanudas Gaikwad Breakdown of academic impact, for papers by Karen SL Lam Breakdown of academic impact, for papers by Kengo Azushima Breakdown of academic impact, for papers by Gaetano Pannitteri Breakdown of academic impact, for papers by Flori R. Sari
Rankless by CCL
2026